Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.37 |
| ▸ | MC4R | P32245 | 2/20 | 0.36 |
| ▸ | MC5R | P33032 | 2/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169851 | 0.89 | ROCK2 (0.34) | GRM2 | |
| SCHEMBL2169470 | 0.89 | KCNH2 (0.35) | GRM2 | |
| SCHEMBL2170561 | 0.88 | KCNH2 (0.35) | GRM2 | |
| SCHEMBL591977 | 0.87 | GRM2 (0.38) | GRM2 | |
| SCHEMBL592200 | 0.87 | GRM2 (0.38) | GRM2 | |
| SCHEMBL591668 | 0.87 | GRM2 (0.38) | GRM2 | |
| SCHEMBL2170046 | 0.87 | GRM2 (0.36) | GRM2 | |
| SCHEMBL592974 | 0.85 | GRM2 (0.36) | GRM2 | |
| SCHEMBL590050 | 0.85 | GRM2 (0.36) | GRM2 | |
| SCHEMBL589903 | 0.85 | GRM2 (0.36) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346862-B1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | claimed |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | claimed |
| EP-2346862-A1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010041219-A1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | claimed |
| EP-2346862-B1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2346862-A1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010041219-A1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | UQCRB, XDH, TOP2B | GRM2 4123/4885MC4R 1981/4885MC5R 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.